IJC Heart and Vasculature最新文献_第7页

Bibliometric analysis of levosimendan 左西孟旦的文献计量学分析。

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-02-01 DOI: 10.1016/j.ijcha.2024.101571

Xian-Shu Zhao , Yi-Ping Yu , Yun-Tai Yao , the Evidence in Cardiovascular Anesthesia (EICA) Group

Background

Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.

Methods

LEVO-related publications from 1990 to 2023 were searched and retrieved in the Web of Science Core Collection (WoSCC) and analyzed with VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix and Rstudio for publication dates, countries/regions, institutions, authors, keywords, journals, and references.

Results

Finally, a total of 1,432 LEVO-related articles were included in the present study. Annual LEVO-related publications have been increased yearly. The United States was the most productive country with 243 articles. The University of Helsinkin published 69 articles in the field of LEVO, which were the most productive institution among all the institutions. Of all the authors, professor Pollesello,Piero was the most productive author with 62 articles. Moreover, the results of the co-citation analysis and citation bursts analysis revealed that the safety and effectiveness of LEVO were the global research trends and potential hot spots.

Conclusions

This study systematically summarizes the current status in the field of LEVO and provides insights into the research focuses and future hotspots.

背景：左西孟旦（Levosimendan， LEVO）是一种钙敏化剂和三磷酸腺苷依赖性钾通道打开剂，几十年来被广泛用于内科和外科患者治疗晚期心力衰竭（HF）、右心衰、心源性休克、takotsubo心肌病、肺动脉高压等。目前，由于当前LEVO出版物的范围有限且缺乏全面的数据，因此开展需要综合信息和可量化结果的新研究的障碍越来越大。因此，本研究旨在利用文献计量学软件，识别levo相关出版物的研究趋势和热点。方法：在Web of Science Core Collection （WoSCC）中检索1990 ~ 2023年的levo相关文献，使用VOSviewer、CiteSpace、Scimago Graphica、R-bibliometrix和Rstudio等软件对出版日期、国家/地区、机构、作者、关键词、期刊和参考文献进行分析。结果：最终，本研究共纳入了1432篇与levo相关的文章。与lego相关的年度出版物逐年增加。美国是最多产的国家，有243条。赫尔辛基大学在LEVO领域发表了69篇论文，是所有机构中产出最多的机构。在所有作者中，波列塞罗教授，皮耶罗是最多产的作者，有62篇文章。此外，共被引分析和引文爆发分析结果表明，LEVO的安全性和有效性是全球研究的趋势和潜在热点。结论：本研究系统总结了LEVO领域的现状，并对研究重点和未来热点提出了见解。

{"title":"Bibliometric analysis of levosimendan","authors":"Xian-Shu Zhao , Yi-Ping Yu , Yun-Tai Yao , the Evidence in Cardiovascular Anesthesia (EICA) Group","doi":"10.1016/j.ijcha.2024.101571","DOIUrl":"10.1016/j.ijcha.2024.101571","url":null,"abstract":"<div><h3>Background</h3><div>Levosimendan (LEVO), a calcium sensitizer and adenosine triphosphate-dependent potassium channel opener, has been widely used for decades in medical and surgical patients for advanced heart failure (HF), right ventricular failure, cardiogenic shock, takotsubo cardiomyopathy, pulmonary hypertension, and so on. Currently, as the limited scope and lack of comprehensive data in current LEVO publications, there is an increasing obstacle to conducting new studies that require integrated information and quantifiable results. Thus, the current study was performed to identify the research trends and hot spots in LEVO-related publications using bibliometric software.</div></div><div><h3>Methods</h3><div>LEVO-related publications from 1990 to 2023 were searched and retrieved in the Web of Science Core Collection (WoSCC) and analyzed with VOSviewer, CiteSpace, Scimago Graphica, R-bibliometrix and Rstudio for publication dates, countries/regions, institutions, authors, keywords, journals, and references.</div></div><div><h3>Results</h3><div>Finally, a total of 1,432 LEVO-related articles were included in the present study. Annual LEVO-related publications have been increased yearly. The United States was the most productive country with 243 articles. The University of Helsinkin published 69 articles in the field of LEVO, which were the most productive institution among all the institutions. Of all the authors, professor Pollesello,Piero was the most productive author with 62 articles. Moreover, the results of the co-citation analysis and citation bursts analysis revealed that the safety and effectiveness of LEVO were the global research trends and potential hot spots.</div></div><div><h3>Conclusions</h3><div>This study systematically summarizes the current status in the field of LEVO and provides insights into the research focuses and future hotspots.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"56 ","pages":"Article 101571"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11719333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142971090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipoprotein(a) and the risk of type I cardiorenal syndrome in patients with coronary artery disease: A retrospective clinical study 脂蛋白(a)与冠心病患者I型心肾综合征的风险：一项回顾性临床研究

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-02-01 DOI: 10.1016/j.ijcha.2024.101568

Zhenhua Jiang, Hailiang Ma, Jianqiang Meng, Dewen Zhu, Yuanben Lu

Objective

The present study aimed to investigate the correlation between lipoprotein(a) (Lp-a) and coronary artery disease (CAD) complicated by type I cardiorenal syndrome (CRS).

Methods

We conducted a retrospective analysis of patients diagnosed with CAD admitted to the Department of Cardiovascular Medicine at Shaoxing Central Hospital from January 2021 to December 2022, with chief complaints of “chest distress and dyspnea.” Patient demographic data, biochemical indicators (including blood lipid levels and serum creatinine), cardiac function markers (such as pro-brain natriuretic peptide, pro-BNP), echocardiography, and coronary angiography results were collected. Patients were categorized into two groups based on estimated glomerular filtration rate (e-GFR): the CRS group (e-GFR < 60 mL/min/1.73 m²) and the simple heart failure group (SHF group, e-GFR ≥ 60 mL/min/1.73 m²). A comparative analysis of baseline characteristics, lipid profiles, ejection fraction (LVEF), left atrial size (LA), end-diastolic interventricular septal thickness (IVSd), left ventricular end-diastolic dimension (LVEDD), and left ventricular end-systolic dimension (LVESD) between the two groups was performed. Multivariable logistic regression analysis was applied to assess the association between serum lipoprotein(a) (Lp-a) levels and the occurrence of CRS.

Results

A total of 269 patients were included, comprising 149 males and 120 females with an average age of 76.0 ± 11.4 years. Significant differences were observed between the CRS and SHF groups in terms of age, history of hypertension, diabetes, myocardial infarction, serum triglycerides, Lp-a, and creatinine (all P < 0.05). Spearman’s correlation analysis revealed an inverse relationship between Lp-a and e-GFR (r = -0.588, P < 0.05). Multivariable logistic regression analysis indicated that Lp-a (OR = 1.980, 95 % CI: 1.269–2.992, P = 0.027) and age (OR = 1.584, 95 % CI: 0.955–1.913, P = 0.006) were positively associated with the development of CRS.

Conclusion

Serum Lp-a levels are positively correlated with the occurrence of CRS, potentially serving as an independent risk factor for CRS.

目的：探讨脂蛋白(a) （Lp-a）与冠心病（CAD）合并I型心肾综合征（CRS）的相关性。方法：我们对2021年1月至2022年12月在绍兴市中心医院心血管内科确诊为CAD的患者进行回顾性分析，这些患者的主诉为“胸闷和呼吸困难”。收集患者人口学资料、生化指标（包括血脂水平、血清肌酐）、心功能指标（如脑利钠肽、bnp前体）、超声心动图、冠状动脉造影结果。根据估计的肾小球滤过率（e-GFR）将患者分为两组：CRS组（e-GFR < 60 mL/min/1.73 m2）和单纯性心力衰竭组（SHF组，e-GFR≥60 mL/min/1.73 m2）。比较分析两组患者的基线特征、血脂、射血分数（LVEF）、左房尺寸（LA）、舒张末期室间隔厚度（IVSd）、左室舒张末期尺寸（LVEDD）和左室收缩末期尺寸（LVESD）。采用多变量logistic回归分析评估血清脂蛋白(a) （Lp-a）水平与CRS发生的关系。结果：共纳入269例患者，其中男性149例，女性120例，平均年龄76.0±11.4岁。CRS组与SHF组在年龄、高血压史、糖尿病史、心肌梗死史、血清甘油三酯、Lp-a、肌酐等指标差异均有统计学意义（P < 0.05）。Spearman相关分析显示，Lp-a与e-GFR呈负相关（r = -0.588, P < 0.05）。多变量logistic回归分析显示，Lp-a （OR = 1.980, 95% CI: 1.269 ~ 2.992, P = 0.027）和年龄（OR = 1.584, 95% CI: 0.955 ~ 1.913, P = 0.006）与CRS的发生呈正相关。结论：血清Lp-a水平与CRS发生呈正相关，可能是CRS发生的独立危险因素。

{"title":"Lipoprotein(a) and the risk of type I cardiorenal syndrome in patients with coronary artery disease: A retrospective clinical study","authors":"Zhenhua Jiang, Hailiang Ma, Jianqiang Meng, Dewen Zhu, Yuanben Lu","doi":"10.1016/j.ijcha.2024.101568","DOIUrl":"10.1016/j.ijcha.2024.101568","url":null,"abstract":"<div><h3>Objective</h3><div>The present study aimed to investigate the correlation between lipoprotein(a) (Lp-a) and coronary artery disease (CAD) complicated by type I cardiorenal syndrome (CRS).</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of patients diagnosed with CAD admitted to the Department of Cardiovascular Medicine at Shaoxing Central Hospital from January 2021 to December 2022, with chief complaints of “chest distress and dyspnea.” Patient demographic data, biochemical indicators (including blood lipid levels and serum creatinine), cardiac function markers (such as pro-brain natriuretic peptide, pro-BNP), echocardiography, and coronary angiography results were collected. Patients were categorized into two groups based on estimated glomerular filtration rate (e-GFR): the CRS group (e-GFR < 60 mL/min/1.73 m<sup>2</sup>) and the simple heart failure group (SHF group, e-GFR ≥ 60 mL/min/1.73 m<sup>2</sup>). A comparative analysis of baseline characteristics, lipid profiles, ejection fraction (LVEF), left atrial size (LA), end-diastolic interventricular septal thickness (IVSd), left ventricular end-diastolic dimension (LVEDD), and left ventricular end-systolic dimension (LVESD) between the two groups was performed. Multivariable logistic regression analysis was applied to assess the association between serum lipoprotein(a) (Lp-a) levels and the occurrence of CRS.</div></div><div><h3>Results</h3><div>A total of 269 patients were included, comprising 149 males and 120 females with an average age of 76.0 ± 11.4 years. Significant differences were observed between the CRS and SHF groups in terms of age, history of hypertension, diabetes, myocardial infarction, serum triglycerides, Lp-a, and creatinine (all P < 0.05). Spearman’s correlation analysis revealed an inverse relationship between Lp-a and e-GFR (r = -0.588, P < 0.05). Multivariable logistic regression analysis indicated that Lp-a (OR = 1.980, 95 % CI: 1.269–2.992, P = 0.027) and age (OR = 1.584, 95 % CI: 0.955–1.913, P = 0.006) were positively associated with the development of CRS.</div></div><div><h3>Conclusion</h3><div>Serum Lp-a levels are positively correlated with the occurrence of CRS, potentially serving as an independent risk factor for CRS.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"56 ","pages":"Article 101568"},"PeriodicalIF":2.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BDNF-induced BDNF release: A virtuous loop for the cardioprotective effects of exercise in post-ischemic heart failure

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-02-01 DOI: 10.1016/j.ijcha.2025.101623

Abdulbaset Maroofi , Fatemeh Safari , Asghar Abbasi

引用次数: 0

Repeated heart rate variability monitoring after myocardial infraction – Cohort profile of the MI-ECG study

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-01-26 DOI: 10.1016/j.ijcha.2025.101619

Teemu Pukkila , Jani Rankinen , Leo-Pekka Lyytikäinen , Niku Oksala , Kjell Nikus , Esa Räsänen , Jussi Hernesniemi

The purpose of this study was to monitor heart rate variability (HRV) parameters after myocardial infarction (MI), addressing the ongoing controversy regarding their prognostic value. HRV was measured via Holter monitoring during the acute phase around the time of discharge and again two weeks later during recovery. Our findings show that HRV parameters remained stable during the initial weeks post-MI, indicating that the timing of Holter monitoring in this period is not critical.

Several HRV parameters were significantly correlated with MI type, Killip class, and left ventricular ejection fraction (LVEF), with reduced HRV observed in STEMI patients and those with decompensated heart failure. However, after adjusting for GRACE score and LVEF, the prognostic value of most HRV measures for predicting future cardiac events diminished. Notably, detrended fluctuation analysis DFA1 α₂ yielded a significant hazard ratio (HR) of 0.79 when adjusted for the GRACE score. However, this significance diminished after adjusting for LVEF (HR = 0.84).

In conclusion, HRV parameters reflect MI severity and correlate with clinical characteristics, but their independent predictive value for future cardiac events is limited when adjusted for established risk factors such as LVEF and GRACE score.

{"title":"Repeated heart rate variability monitoring after myocardial infraction – Cohort profile of the MI-ECG study","authors":"Teemu Pukkila , Jani Rankinen , Leo-Pekka Lyytikäinen , Niku Oksala , Kjell Nikus , Esa Räsänen , Jussi Hernesniemi","doi":"10.1016/j.ijcha.2025.101619","DOIUrl":"10.1016/j.ijcha.2025.101619","url":null,"abstract":"<div><div>The purpose of this study was to monitor heart rate variability (HRV) parameters after myocardial infarction (MI), addressing the ongoing controversy regarding their prognostic value. HRV was measured via Holter monitoring during the acute phase around the time of discharge and again two weeks later during recovery. Our findings show that HRV parameters remained stable during the initial weeks post-MI, indicating that the timing of Holter monitoring in this period is not critical.</div><div>Several HRV parameters were significantly correlated with MI type, Killip class, and left ventricular ejection fraction (LVEF), with reduced HRV observed in STEMI patients and those with decompensated heart failure. However, after adjusting for GRACE score and LVEF, the prognostic value of most HRV measures for predicting future cardiac events diminished. Notably, detrended fluctuation analysis DFA1 α<sub>2</sub> yielded a significant hazard ratio (HR) of 0.79 when adjusted for the GRACE score. However, this significance diminished after adjusting for LVEF (HR = 0.84).</div><div>In conclusion, HRV parameters reflect MI severity and correlate with clinical characteristics, but their independent predictive value for future cardiac events is limited when adjusted for established risk factors such as LVEF and GRACE score.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"57 ","pages":"Article 101619"},"PeriodicalIF":2.5,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between sleep disorders and subsequent heart failure

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-01-25 DOI: 10.1016/j.ijcha.2025.101618

Jamschid Sedighi , Mark Luedde , Julia Gaensbacher-Kunzendorf , Hans-Joerg Hippe , Pascal Bauer , Birgit Assmus , Samuel Sossalla , Karel Kostev

Background

Sleep disorders are prevalent conditions that may influence the progression of various heart diseases. However, the relationship between sleep disorders and the onset of heart failure (HF) remains unclear.

Objective

The purpose of this study was to investigate whether sleep disorders are associated with an increased risk of developing HF.

Methods

We conducted a retrospective cohort study using data from 1,293 general practices across Germany sourced from the IQVIA Disease Analyzer database. The study included patients with an initial diagnosis of HF (ICD-10 code: I50) between January 2010 and December 2022 (index data) These patients were matched with control subjects without HF based on age, sex, and pre-existing conditions. The primary outcome was the association between prior sleep disorder diagnoses and the subsequent development of HF. Data were available for 9,345,246 individuals, of which 406,265 had a history of HF.

Results

The study analyzed data from 123,516 patients with HF and an equal number of matched controls. The mean age of participants was 73.3–73.4 (SD 12.4) years, with 53.2% being women. Sleep disorders diagnosed prior to the onset of HF were significantly associated with an increased risk of developing HF. This association was consistent across different types of sleep disorders overall (OR: 1.22; 95%CI: 1.19–1.24) as well as insomnia (OR: 1.26; 95%CI: 1.21–1.31), sleep apnea (OR: 1.20; 95%CI: 1.15–1.25), and unspecified sleep disorders (OR: 1.21; 95%CI: 1.18–1.25).

Conclusion

In this large cohort of outpatients, a prior diagnosis of sleep disorders was linked to a higher incidence of HF. These findings suggest that sleep disorders may serve as a risk factor for the development of HF, highlighting the need for early identification and management of sleep disturbances in at-risk populations. Addressing these disorders in clinical practice could represent a pivotal step towards better cardiovascular health and patient care.

{"title":"Association between sleep disorders and subsequent heart failure","authors":"Jamschid Sedighi , Mark Luedde , Julia Gaensbacher-Kunzendorf , Hans-Joerg Hippe , Pascal Bauer , Birgit Assmus , Samuel Sossalla , Karel Kostev","doi":"10.1016/j.ijcha.2025.101618","DOIUrl":"10.1016/j.ijcha.2025.101618","url":null,"abstract":"<div><h3>Background</h3><div>Sleep disorders are prevalent conditions that may influence the progression of various heart diseases. However, the relationship between sleep disorders and the onset of heart failure (HF) remains unclear.</div></div><div><h3>Objective</h3><div>The purpose of this study was to investigate whether sleep disorders are associated with an increased risk of developing HF.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using data from 1,293 general practices across Germany sourced from the IQVIA Disease Analyzer database. The study included patients with an initial diagnosis of HF (ICD-10 code: I50) between January 2010 and December 2022 (index data) These patients were matched with control subjects without HF based on age, sex, and pre-existing conditions. The primary outcome was the association between prior sleep disorder diagnoses and the subsequent development of HF. Data were available for 9,345,246 individuals, of which 406,265 had a history of HF.</div></div><div><h3>Results</h3><div>The study analyzed data from 123,516 patients with HF and an equal number of matched controls. The mean age of participants was 73.3–73.4 (SD 12.4) years, with 53.2% being women. Sleep disorders diagnosed prior to the onset of HF were significantly associated with an increased risk of developing HF. This association was consistent across different types of sleep disorders overall (OR: 1.22; 95%CI: 1.19–1.24) as well as insomnia (OR: 1.26; 95%CI: 1.21–1.31), sleep apnea (OR: 1.20; 95%CI: 1.15–1.25), and unspecified sleep disorders (OR: 1.21; 95%CI: 1.18–1.25).</div></div><div><h3>Conclusion</h3><div>In this large cohort of outpatients, a prior diagnosis of sleep disorders was linked to a higher incidence of HF. These findings suggest that sleep disorders may serve as a risk factor for the development of HF, highlighting the need for early identification and management of sleep disturbances in at-risk populations. Addressing these disorders in clinical practice could represent a pivotal step towards better cardiovascular health and patient care.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"57 ","pages":"Article 101618"},"PeriodicalIF":2.5,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143104170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2025-01-24 DOI: 10.1016/j.ijcha.2025.101622

Anouk Achten , Jerremy Weerts , Johan van Koll , Mohammed Ghossein , Sanne G.J. Mourmans , Arantxa Barandiarán Aizpurua , Antonius M.W. van Stipdonk , Kevin Vernooy , Frits W. Prinzen , Hans-Peter Brunner-La Rocca , Christian Knackstedt , Vanessa P.M. van Empel

Background

The pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) is heterogeneous and incompletely understood. This study evaluated the presence of a ventricular conduction delay (VCD) phenotype in HFpEF through QRS duration and vectorcardiographic QRS area, and their relation to adverse outcomes.

Methods

This study included consecutive ambulatory HFpEF patients. Baseline QRS duration was obtained from an electrocardiogram (ECG). QRS area was derived from vectorcardiographic analyses of the ECG. QRS duration and area were assessed and analysed as categorical (<100 ms, 100–119 ms, ≥120 ms; ≤ 43.1 µVs, >43.1 µVs) and continuous variables to determine the relation to the composite outcome of HF hospitalisation and all-cause mortality.

Results

349 HFpEF patients were included of whom 70 % had a QRS duration < 100 ms compared to 21 % with QRS duration 100–119 ms and 9 % with QRS duration ≥120 ms. 87 (25 %) patients had QRS area >43.1 µVs. Only 4 % had a QRS area ≥69µVs, indicating delayed lateral wall activation. After a median of 3 years follow-up, 30 % of the patients had an adverse outcome. Longer QRS duration but not larger QRS area was associated with more adverse outcomes on both categorical and continuous scales (HR per 5 ms increase = 1.06, P = 0.033). This prognostic association was mainly present in males.

Conclusion

HFpEF patients have a low prevalence of a VCD phenotype(9 % QRS duration ≥120 ms;4 % a QRS area ≥69 µVs). However, QRS duration >100 ms was present in 30 % and was an independent predictor for adverse outcomes. Future efforts are needed to understand the mechanisms underlying the association of QRS duration and adverse outcomes, and to determine its clinical implications.

{"title":"Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction","authors":"Anouk Achten , Jerremy Weerts , Johan van Koll , Mohammed Ghossein , Sanne G.J. Mourmans , Arantxa Barandiarán Aizpurua , Antonius M.W. van Stipdonk , Kevin Vernooy , Frits W. Prinzen , Hans-Peter Brunner-La Rocca , Christian Knackstedt , Vanessa P.M. van Empel","doi":"10.1016/j.ijcha.2025.101622","DOIUrl":"10.1016/j.ijcha.2025.101622","url":null,"abstract":"<div><h3>Background</h3><div>The pathophysiology of heart failure (HF) with preserved ejection fraction (HFpEF) is heterogeneous and incompletely understood. This study evaluated the presence of a ventricular conduction delay (VCD) phenotype in HFpEF through QRS duration and vectorcardiographic QRS area, and their relation to adverse outcomes.</div></div><div><h3>Methods</h3><div>This study included consecutive ambulatory HFpEF patients. Baseline QRS duration was obtained from an electrocardiogram (ECG). QRS area was derived from vectorcardiographic analyses of the ECG. QRS duration and area were assessed and analysed as categorical (<100 ms, 100–119 ms, ≥120 ms; ≤ 43.1 µVs, >43.1 µVs) and continuous variables to determine the relation to the composite outcome of HF hospitalisation and all-cause mortality.</div></div><div><h3>Results</h3><div>349 HFpEF patients were included of whom 70 % had a QRS duration < 100 ms compared to 21 % with QRS duration 100–119 ms and 9 % with QRS duration ≥120 ms. 87 (25 %) patients had QRS area >43.1 µVs. Only 4 % had a QRS area ≥69µVs, indicating delayed lateral wall activation. After a median of 3 years follow-up, 30 % of the patients had an adverse outcome. Longer QRS duration but not larger QRS area was associated with more adverse outcomes on both categorical and continuous scales (HR per 5 ms increase = 1.06, P = 0.033). This prognostic association was mainly present in males.</div></div><div><h3>Conclusion</h3><div>HFpEF patients have a low prevalence of a VCD phenotype(9 % QRS duration ≥120 ms;4 % a QRS area ≥69 µVs). However, QRS duration >100 ms was present in 30 % and was an independent predictor for adverse outcomes. Future efforts are needed to understand the mechanisms underlying the association of QRS duration and adverse outcomes, and to determine its clinical implications.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"57 ","pages":"Article 101622"},"PeriodicalIF":2.5,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143172057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease NT-proBNP在高血压疾病房颤筛查中的作用

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2024-12-01 DOI: 10.1016/j.ijcha.2024.101549

Gina Sado , Katrin Kemp Gudmundsdottir , Carl Bonander , Mattias Ekström , Johan Engdahl , Emma Svennberg

Background

Atrial fibrillation (AF) screening should be considered in elderly patients with high risk of stroke, which include individuals with hypertension. The biomarker N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can predict incident AF and is increased in hypertensive individuals. The aim of this study is to investigate the incidence of screening-detected AF in elderly individuals in relation to NT-proBNP and hypertension.

Methods

STROKESTOP II is a randomized controlled trial in which 75/76-years-old individuals were invited to a screening study for AF using NT-proBNP as a discriminator of high risk. In this sub-study, a prior hypertension diagnosis was self-reported by participants and measured blood pressure was stratified into hypertension-grades. Individuals with both increased blood pressure (≥140 mmHg) and NT-proBNP ≥ 125 ng/L were defined as a high-risk group. The lowest risk-group was defined as normotensive participants with NT-proBNP < 125 ng/L.

Results

NT-proBNP increased gradually for every hypertension-grade above hypertension-grade 1 compared to normotensive participants. Screening-detected AF was most common in normotensive participants with increased NT-proBNP (n = 90/1922, 4.7 %), followed by patients with both NT-proBNP > 125 ng/l and SBP ≥ 140 mmHg, (AF = 65/1741, 3.7 %) compared to the low-risk group (AF = 2/1444, 0.1 %), p < 0.001.

Conclusion

NT-proBNP is elevated in elderly patients with hypertension and increases with grades of hypertensive disease. NT-proBNP is a strong predictor of AF regardless of high blood pressure, and the risk for screening-detected AF is very low in participants with normal blood pressure and low NT-proBNP. A combination of blood pressure and NT-proBNP could identify suitable participants for AF screening.

背景：老年卒中高危患者（包括高血压患者）应考虑房颤筛查。脑利钠肽n端原激素（NT-proBNP）可以预测房颤的发生，并且在高血压个体中升高。本研究的目的是探讨老年人筛查检测到的房颤发病率与NT-proBNP和高血压的关系。方法strokestop II是一项随机对照试验，邀请75/76岁的个体使用NT-proBNP作为鉴别高风险的AF筛查研究。在这个亚研究中，参与者自我报告先前的高血压诊断，并将测量的血压分层为高血压等级。血压升高（≥140 mmHg）且NT-proBNP≥125 ng/L的个体被定义为高危组。最低风险组定义为NT-proBNP和lt；125 ng / L。结果1级以上高血压患者的snt - probnp均较正常高血压患者逐渐升高。筛查检测到房颤最常见于NT-proBNP升高的正常血压参与者（n = 90/1922, 4.7%），其次是NT-proBNP和gt；125 ng/l和收缩压≥140 mmHg，（AF = 65/1741, 3.7%）与低危组（AF = 2/1444, 0.1%）相比，p <；0.001.结论nt - probnp在老年高血压患者中升高，并随高血压疾病的加重而升高。NT-proBNP是房颤的一个强有力的预测因子，与高血压无关，在血压正常且NT-proBNP低的参与者中，筛查检测到房颤的风险非常低。结合血压和NT-proBNP可以确定合适的参与者进行房颤筛查。

{"title":"The role of NT-proBNP in screening for atrial fibrillation in hypertensive disease","authors":"Gina Sado , Katrin Kemp Gudmundsdottir , Carl Bonander , Mattias Ekström , Johan Engdahl , Emma Svennberg","doi":"10.1016/j.ijcha.2024.101549","DOIUrl":"10.1016/j.ijcha.2024.101549","url":null,"abstract":"<div><h3>Background</h3><div>Atrial fibrillation (AF) screening should be considered in elderly patients with high risk of stroke, which include individuals with hypertension. The biomarker N-terminal prohormone of brain natriuretic peptide (NT-proBNP) can predict incident AF and is increased in hypertensive individuals. The aim of this study is to investigate the incidence of screening-detected AF in elderly individuals in relation to NT-proBNP and hypertension.</div></div><div><h3>Methods</h3><div>STROKESTOP II is a randomized controlled trial in which 75/76-years-old individuals were invited to a screening study for AF using NT-proBNP as a discriminator of high risk. In this sub-study, a prior hypertension diagnosis was self-reported by participants and measured blood pressure was stratified into hypertension-grades. Individuals with both increased blood pressure (≥140 mmHg) and NT-proBNP ≥ 125 ng/L were defined as a high-risk group. The lowest risk-group was defined as normotensive participants with NT-proBNP < 125 ng/L.</div></div><div><h3>Results</h3><div>NT-proBNP increased gradually for every hypertension-grade above hypertension-grade 1 compared to normotensive participants. Screening-detected AF was most common in normotensive participants with increased NT-proBNP (n = 90/1922, 4.7 %), followed by patients with both NT-proBNP > 125 ng/l and SBP ≥ 140 mmHg, (AF = 65/1741, 3.7 %) compared to the low-risk group (AF = 2/1444, 0.1 %), p < 0.001.</div></div><div><h3>Conclusion</h3><div>NT-proBNP is elevated in elderly patients with hypertension and increases with grades of hypertensive disease. NT-proBNP is a strong predictor of AF regardless of high blood pressure, and the risk for screening-detected AF is very low in participants with normal blood pressure and low NT-proBNP. A combination of blood pressure and NT-proBNP could identify suitable participants for AF screening.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"55 ","pages":"Article 101549"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and validation of machine learning-derived frailty index in predicting outcomes of patients undergoing percutaneous coronary intervention 基于机器学习的虚弱指数预测经皮冠状动脉介入治疗患者预后的发展和验证

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2024-12-01 DOI: 10.1016/j.ijcha.2024.101511

John T.Y. Soong , L.F. Tan , Rodney Y.H. Soh , W.B. He , Andie H. Djohan , H.W. Sim , T.C. Yeo , H.C. Tan , Mark Y.Y. Chan , C.H. Sia , M.L. Feng

Introduction

Frailty is associated with increased mortality in patients with percutaneous coronary intervention (PCI). Existing operationalized frailty measurement tools are limited and require resource intensive process. We developed and validated a tool to identify and stratify frailty using collected data for patients who underwent PCI and explored its predictive power to predict adverse clinical outcomes post PCI.

Methods

Between 2014 and 2015, 1,732 patients who underwent semi-urgent or elective PCI in a tertiary centre were included. Variables including demographics, co-morbidities, investigations and clinical outcomes to 33 ± 37 months were analysed. Logistic regression model and Extreme Gradient Boosting (XGBoost) machine learning model were constructed to identify predictors of adverse clinical outcomes post PCI. The final models’ predicted probabilities were assessed with area under receiver operating characteristic curve (AUC).

Results

With model analysis, frailty index (FI), age and gender were the 3 most important features for adverse clinical outcomes prediction, with FI contributing the most. After adjustment, the odds of FI to predict cardiac death and in-hospital death post PCI remained significant [1.94 (95 %CI1.79–2.10); p < 0.001, 2.04(95 %CI 1.87–2.23); p < 0.001 respectively]. The XGBoost machine learning models improved predictive power for cardiac death [AUC 0.83(95 %CI 0.80–0.86)] and in hospital death [AUC 0.83(95 %CI 0.80–0.86)] post PCI compared to logistic regression models.

Conclusion

The resultant model developed using novel machine learning methodologies had good predictive power for significant clinical outcomes post PCI with potential to be automated within hospital information systems.

经皮冠状动脉介入治疗（PCI）患者虚弱与死亡率增加相关。现有的可操作的脆弱性测量工具是有限的，并且需要资源密集型的过程。我们开发并验证了一种工具，通过收集PCI患者的数据来识别和分层虚弱，并探索其预测PCI后不良临床结果的预测能力。方法2014年至2015年，在三级中心接受半紧急或选择性PCI治疗的1732例患者纳入研究。包括人口统计学、合并症、调查和33±37个月的临床结果等变量进行分析。构建Logistic回归模型和极端梯度增强（XGBoost）机器学习模型来识别PCI后不良临床结果的预测因素。最终模型的预测概率用受试者工作特征曲线下面积（AUC）进行评估。结果通过模型分析，衰弱指数（FI）、年龄和性别是预测临床不良结局最重要的3个特征，其中FI贡献最大。调整后，FI预测PCI术后心源性死亡和院内死亡的几率仍然显著[1.94 (95% CI1.79-2.10)；p & lt;0.001, 2.04(95% ci 1.87-2.23)；p & lt;分别为0.001)。与logistic回归模型相比，XGBoost机器学习模型提高了PCI后心脏死亡[AUC 0.83(95% CI 0.80-0.86)]和住院死亡[AUC 0.83(95% CI 0.80-0.86)]的预测能力。结论：使用新型机器学习方法开发的模型对PCI后的重要临床结果具有良好的预测能力，并有可能在医院信息系统中实现自动化。

{"title":"Development and validation of machine learning-derived frailty index in predicting outcomes of patients undergoing percutaneous coronary intervention","authors":"John T.Y. Soong , L.F. Tan , Rodney Y.H. Soh , W.B. He , Andie H. Djohan , H.W. Sim , T.C. Yeo , H.C. Tan , Mark Y.Y. Chan , C.H. Sia , M.L. Feng","doi":"10.1016/j.ijcha.2024.101511","DOIUrl":"10.1016/j.ijcha.2024.101511","url":null,"abstract":"<div><h3>Introduction</h3><div>Frailty is associated with increased mortality in patients with percutaneous coronary intervention (PCI). Existing operationalized frailty measurement tools are limited and require resource intensive process. We developed and validated a tool to identify and stratify frailty using collected data for patients who underwent PCI and explored its predictive power to predict adverse clinical outcomes post PCI.</div></div><div><h3>Methods</h3><div>Between 2014 and 2015, 1,732 patients who underwent semi-urgent or elective PCI in a tertiary centre were included. Variables including demographics, co-morbidities, investigations and clinical outcomes to 33 ± 37 months were analysed. Logistic regression model and Extreme Gradient Boosting (XGBoost) machine learning model were constructed to identify predictors of adverse clinical outcomes post PCI. The final models’ predicted probabilities were assessed with area under receiver operating characteristic curve (AUC).</div></div><div><h3>Results</h3><div>With model analysis, frailty index (FI), age and gender were the 3 most important features for adverse clinical outcomes prediction, with FI contributing the most. After adjustment, the odds of FI to predict cardiac death and in-hospital death post PCI remained significant [1.94 (95 %CI1.79–2.10); p < 0.001, 2.04(95 %CI 1.87–2.23); p < 0.001 respectively]. The XGBoost machine learning models improved predictive power for cardiac death [AUC 0.83(95 %CI 0.80–0.86)] and in hospital death [AUC 0.83(95 %CI 0.80–0.86)] post PCI compared to logistic regression models.</div></div><div><h3>Conclusion</h3><div>The resultant model developed using novel machine learning methodologies had good predictive power for significant clinical outcomes post PCI with potential to be automated within hospital information systems.</div></div>","PeriodicalId":38026,"journal":{"name":"IJC Heart and Vasculature","volume":"55 ","pages":"Article 101511"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory gut-heart interactions: Is there a link between inflammatory bowel disease and atrial fibrillation? 炎症性肠-心相互作用：炎症性肠病和房颤之间是否存在联系？

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2024-12-01 DOI: 10.1016/j.ijcha.2024.101537

Dobromir Dobrev, Anke C. Fender

引用次数: 0

Towards improved detection of subclinical atrial fibrillation – Who could benefit from targeted screening? 改进亚临床房颤的检测——谁能从靶向筛查中受益？

IF 2.5 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

IJC Heart and Vasculature

Pub Date : 2024-12-01 DOI: 10.1016/j.ijcha.2024.101550

Anke C. Fender, Dobromir Dobrev